N-[2-(4-methoxyphenyl)ethyl]-1-(4-propan-2-yloxyphenyl)ethane-1,2-diamine | 1192408-05-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 石蒜科生物碱
• 英文名称: N-[2-(4-methoxyphenyl)ethyl]-1-(4-propan-2-yloxyphenyl)ethane-1,2-diamine
• CAS: 1192408-05-1
• 化学式: C₂₀H₂₈N₂O₂
• 分子量: 328.455
• InChiKey: HBLKTPSLXQDAPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  56.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[2-(4-methoxyphenyl)ethyl]-1-(4-propan-2-yloxyphenyl)ethane-1,2-diamine 、 N,N'-羰基二咪唑 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 3-[2-(4-methoxyphenyl)ethyl]-4-[(4-isopropyloxy)-phenyl]-2-imidazolidinone
  参考文献：
  名称：

  Selective Kv1.5 Blockers: Development of (R)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a Potential Treatment for Atrial Arrhythmia

  摘要：

  Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.

  DOI：

  10.1021/jm901042m
• 作为产物：
  描述：

  在 盐酸 、 锌 作用下， 以 乙醇 、 水 为溶剂， 生成 N-[2-(4-methoxyphenyl)ethyl]-1-(4-propan-2-yloxyphenyl)ethane-1,2-diamine
  参考文献：
  名称：

  Selective Kv1.5 Blockers: Development of (R)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a Potential Treatment for Atrial Arrhythmia

  摘要：

  Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.

  DOI：

  10.1021/jm901042m